HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo‐Controlled, Ascending‐Dose Phase 1b Study
Authors' conclusion
HDM1002 demonstrated a manageable safety/tolerability profile.
Study context
- Population
- Chinese adults (18–60 years) with BMI ≥ 24.0 kg/m² to ≤ 36.0 kg/m² without diabetesrandomized 5:1, 12 per cohort
- Comparison
- Oral HDM1002 vs placebo for 28 days
- Primary endpoint
- Safety: TEAEs, vital signs, physical examination, ECG and laboratory parameters
Methodological detailsplacebo-controlled, ascending-dose, phase 1b
- Placebo-controlled
- Ascending-dose
- Phase 1b
Primary result
As reported in the abstract
TEAEs
Secondary outcomes
Least squares mean, kg
| Outcome | HDM1002 200 mg QD | HDM1002 100 mg BID | HDM1002 400 mg QD | Placebo |
|---|---|---|---|---|
| Body weight, least squares mean change from baseline | −6.1 | −4.4 | −4.3 | −1.6 |
Glycemia
- No significant effect on glycemia with HDM1002 vs placebo
Pharmacokinetics (PK)
- PK generally dose-proportional
Safety
Discontinuation due to treatment-emergent adverse events (TEAEs)
- Discontinued HDM1002 due to TEAEs
- 2 participants
- Discontinued placebo due to TEAEs
- 0
Original publication
HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo‐Controlled, Ascending‐Dose Phase 1b Study. Obesity (Silver Spring). Published 9 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →